October 23rd, 2024 | 08:00 CEST
Evotec, Nyxoah, BioNTech – Stocks for the future?
The biotechnology and medtech industries are at an exciting turning point, with companies such as Evotec, Nyxoah and BioNTech positioning themselves as leading players in this dynamic field. Their innovative technologies and promising product pipelines could have the potential to fundamentally transform healthcare. Evotec excels in drug discovery expertise, Nyxoah develops groundbreaking solutions for sleep apnea, and BioNTech is a pioneer in mRNA technology. Although Evotec and BioNTech have recently faced challenges, all three companies are well-positioned to benefit from future medical developments.
time to read: 4 minutes | Author: Armin Schulz
ISIN: EVOTEC SE INH O.N. | DE0005664809 , NYXOAH SA | BE0974358906 , BIONTECH SE SPON. ADRS 1 | US09075V1026
Table of contents:
Author
Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
Tag cloud
Shares cloud
Evotec – Waiting for the quarterly figures
Evotec faces significant challenges as investor confidence has been severely shaken. The long-standing CEO Werner Lanthaler's resignation after delayed reporting of insider transactions has thrown the Company into turmoil. In addition, the departure of Dr. Matthias Evers, Chief Business Officer, is causing further concern among investors. Such personnel changes indicate far-reaching restructuring. Amidst this environment, the shares are on a downward spiral, and investors are waiting for November 6. On this day, the Company is set to present its quarterly figures. Analysts are expecting a loss of EUR 0.075 per share.
Despite its challenging situation, Evotec is focusing on strategic partnerships as a growth strategy. A promising collaboration has been established with insulin manufacturer Novo Nordisk to work on innovative cell therapies jointly. This collaboration could be crucial to underpin Evotec's scientific expertise and create access to new markets. In addition, Evotec is working with X-Chem to strengthen its early-stage drug discovery. Such alliances offer the potential for significant milestone and license payments, although specific financial details are still lacking.
With the opening of the new J.POD® facility in Toulouse, Evotec is taking a significant step into the future. This state-of-the-art factory is designed to make biologics production more efficient and is considered the most important milestone for the Company. However, analysts remain cautious. Opinions are divided, as achieving the annual targets is linked to a better-than-expected fourth quarter. It remains to be seen whether the factory will have a positive impact on Evotec's financial recovery. The next quarterly figures could provide further information. The share price has formed a double bottom at EUR 5.20 and is currently trading at EUR 5.805.
Nyxoah – An innovative approach for the treatment of obstructive sleep apnea
Nyxoah is an innovative medical technology company specializing in the development of groundbreaking technologies for the treatment of obstructive sleep apnea (OSA). The main product, Genio®, is a lead- and battery-free hypoglossal neurostimulation system implanted under the chin in a minimally invasive procedure and activated by an external wearable. This technology promises significant relief for millions of sufferers worldwide. Additionally, the study results to date show that Genio® significantly improves patients' quality of life.
The DREAM study of Nyxoah, which is a key element of the company's US approval strategy, has delivered promising results in Spring 2024. A presentation at the Miami International Surgical Sleep Society conference in September 2024 additionally revealed clinically significant improvements in the apnea-hypopnea index (AHI) and quality of life for patients.
Based on the DREAM study the company has completed and submitted the fourth module of its application for approval to the FDA. The approval is expected by the end of 2024 and market launch is planned for the first quarter 2025. The positive response from the research community strengthens Nyxoah's position and offers hope for the many patients suffering from obstructive sleep apnea.
Analysts are optimistic about Nyxoah and have raised the target price to USD 18. The impressive results from the DREAM study and the upcoming FDA approval are boosting investor interest. Although the Company is still experiencing financial losses, the inflow of funds from recent AT-the-Market-Offering further strengthens Nyxoah’s financial position and offers the company the necessary flexibility for a successful market launch in the US. An American investor secured 3 million shares for USD 27 million. At the current share price of USD 9.53, the market capitalization is around USD 327 million.
BioNTech – Suspension of a study
BioNTech recently celebrated a significant victory in the London High Court. The court ruled that two CureVac patents relating to mRNA technology, which are crucial for BioNTech's COVID-19 vaccine, are invalid. This legal victory is part of a larger international dispute between BioNTech, Pfizer and CureVac that is being played out in several countries. BioNTech and Pfizer initially filed the lawsuit in September 2022 after CureVac had previously taken legal action against BioNTech in Germany.
But after the good news, there was a setback. In the US, a Phase III study by BioNTech and OncoC4 for lung cancer therapy was temporarily halted by the FDA. The reason for this is the discovery of different results in different patient groups. BioNTech stated that an independent review indicated possible deviations in the study data. The enrollment of new patients was immediately paused. The therapy of other diseases in which the same antibody candidate is being tested remains unaffected while future steps are being considered.
Despite all this, the BioNTech pipeline is broadly positioned to fight cancer. The planned market entry of the first cancer drug in 2026 is part of a broader strategy supported by significant investments in research and development. Analysts see great potential in this diversification. In addition, BioNTech plans to expand its AI capabilities further to advance personalized medicine. This strategy could strengthen the Company's competitive position in the long term and increase opportunities for investors. The suspension of the study has stopped the share price from soaring and caused an initial correction. The share price fell by 5.58% in Xetra trading and closed at EUR 101.50.
All three companies presented have the potential to become a pearl in the portfolio. Evotec relies on strategic partnerships with Novo Nordisk and X-Chem to strengthen its scientific expertise. Nyxoah has great potential in the area of sleep apnea treatment due to the positive DREAM study and the pursuit of FDA approval. Despite a study that was temporarily stopped, BioNTech has a diversified pipeline, particularly in the area of mRNA technology and oncology.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
